Bookmark

Add to MyYahoo RSS

MannKind News

News on MannKind (Ticker: MNKD) continually updated from thousands of sources around the net.

Friday Jul 11 | The Motley Fool

Is This MannKind's Greatest Risk?

Instead, those predictions swung and missed. The U.S. Food and Drug Administration recently approved the inhaled insulin.

Comment?

Related Topix: Biotech, Food and Drug Administration, Medicine, Insulin (generic), Humulin, Novolin, Diabetes, Health, Marketing

Fri Jul 04, 2014

The Motley Fool

3 Things to Look for in MannKind's Partnership

What's taking so long? I jest. But I'm allowed to. MannKind has been talking about a partnership since before the FDA first rejected the drug f Without a doubt, a partnership is the next big catalyst for the stock now that Afrezza is approved.

Comment?

Related Topix: Biotech, Food and Drug Administration, Medicine, Insulin (generic), Humulin, Novolin, Marketing, Diabetes, Health, Sales

Diabetes Self Management

FDA Approves Inhalable Insulin

On June 27, the US Food and Drug Administration approved Afrezza, a first-in-class inhalable insulin/inhaler combination, for adults with diabetes.

Comment?

Related Topix: Medicine, Insulin (generic), Humulin, Novolin, Healthcare Law, Law, Food and Drug Administration, Diabetes, Health, Biotech, Marketing

Thu Jul 03, 2014

AmericanBankingNews.com

MannKind CFO Matthew J. Pfeffer Sells 20,000 Shares

MannKind CFO Matthew J. Pfeffer sold 20,000 shares of the company's stock in a transaction dated Tuesday, July 1st.

Comment?

Related Topix: Biotech

Freshnews

MannKind Corp Analyst Report; Afrezza is Approved and Future...

MannKind Corporation is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes.

Comment?

Related Topix: Biotech, Medicine, Health, Diabetes, Insulin (generic), Humulin, Novolin

Freshnews

The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, MannKind,...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.

Comment?

Related Topix: Vertex, Biotech, Vertex Pharmaceuticals, Medicine, Healthcare Industry, Financial Markets, Auxilium Pharmaceuticals, QLT

Wed Jul 02, 2014

AmericanBankingNews.com

Insider Buying: Hakan Edstrom Buys 1,692 Shares of MannKind Stock

MannKind COO Hakan Edstrom purchased 1,692 shares of MannKind stock in a transaction dated Monday, June 30th.

Comment?

Related Topix: Biotech

Tue Jul 01, 2014

MedicineNet

Inhaled Insulin Afrezza: FAQ

June 30, 2014 -- Millions of people with type 1 or type 2 diabetes will have another treatment option now that the FDA has approved an inhaled insulin .

Comment?

Related Topix: Medicine, Insulin (generic), Humulin, Novolin, Diabetes, Health, Healthcare Law, Law, Food and Drug Administration, Fulton County, GA, Atlanta, GA, Biotech

SchaeffersResearch.com

Why MannKind Corporation (MNKD) Bears Aren't Panicking

Despite the FDA-inspired boost, though, MNKD bears don't seem to be panicking just yet.

Comment?

Related Topix: Biotech, Financial Markets, Personal Finance, Day Trading

Benzinga

MLV & Co. Downgrades MannKind On Fair Valuation

In a report published Tuesday, MLV & Co analyst Graig C. Suvannavejh downgraded the rating on MannKind Corporation from Buy to Hold, but raised the price target from $10.00 to $11.00.

Comment?

Related Topix: Biotech, Medicine, Insulin (generic), Humulin, Novolin, Diabetes, Health

Mon Jun 30, 2014

MarketNewsVideo

Week Ahead Market Report: June 30, 2014

The US markets are mixed this afternoon, with the Dow down 0.02%, the S&P up 0.12% and the Nasdaq higher by 0.43%.

Comment?

Related Topix: Financial Markets, Biotech, Banking, Bank of America, Financial Services, Business News, Video

Hispanic Business

FDA Approves MannKind's Afrezza; Synageva BioPharma Reports Phase 3...

Afrezza, a fast-acting form of insulin, for adults with the most common form of diabetes, which affects more than 25 million Americans.

Comment?

Related Topix: Synageva BioPharma, Biotech, Medicine, Trimeris, Healthcare Industry, Healthcare Law, Law, Insulin (generic), Humulin, Novolin, Diabetes, Health

Benzinga

General Motors Issues More Recalls, Reach 27 Million Autos Recalled In 2014

With minutes remaining in the trading day for Monday, the Dow traded down 0.13 percent to 16,830.49 while the NASDAQ surged 0.31 percent to 4,411.75.

Comment?

Related Topix: Product Recalls, ClickSoftware Technologies, Human Resources, Software, Construction, Rayonier, Biotech, Startups, ServiceSource

AmericanBankingNews.com

MannKind Trading Up 9.7% on Analyst Upgrade

MannKind shares were up 9.7% on Monday after Brinson Patrick raised their price target on the stock from $12.00 to $15.00, American Banking News reports.

Comment?

Related Topix: Biotech

Benzinga

Stocks To Watch For June 30, 2014

Shares of MannKind jumped 10% in after-hours trading following the conditional FDA approval for Afrezza.

Comment?

Related Topix: Financial Markets, Biotech, Rackspace, Telecom, IT Services, Rackspace Cloud, Rackable Systems, Startups, IBM

Sun Jun 29, 2014

Diabetes Mine

NewsFlash: Inhaled Insulin Afrezza Gets FDA Approval

The third time's the charm for this new formulation of inhalable insulin, the second-ever to make it through the U.S. regulatory process after Pfizer's failed Exubera the better part of a decade ago.

Comment?

Related Topix: Medicine, Insulin (generic), Humulin, Novolin, Healthcare Law, Law, Food and Drug Administration, Biotech, Diabetes

I4U Future Technology News

Diabetics Rejoice: MannKind's Insulin Inhaler Afrezza's FDA-Approved

Fast-acting Afrezza is the size of a referee whistle, making it more convenient to carry around than traditionally bottled insulin or the pens.

Comment?

Related Topix: Biotech, Healthcare Law, Law

Fri Jun 27, 2014

GlobeNewswire

MannKind Corporation Announces FDA Approval of AFREZZA(R); A Novel,...

MannKind Corporation today announced that the U.S. Food & Drug Administration has approved AFREZZA Inhalation Powder to improve glycemic control in adult patients with diabetes mellitus.

Comment?

Related Topix: Food and Drug Administration, Biotech, Medicine, Insulin (generic), Humulin, Novolin, Diabetes, Health

Reuters

UPDATE 1-U.S. FDA approves MannKind's diabetes therapy Afrezza

The U.S. Food and Drug Administration said on Friday it has approved MannKind Corp's inhaled insulin device, Afrezza, capping an arduous journey for the company and its octogenarian founder, Alfred Mann.

Comment?

Related Topix: Food and Drug Administration, Biotech, Diabetes, Health, Insulin (generic), Humulin, Novolin

BioSpace

FDA Approves MannKind Corporation??'s Much Anticipated Diabetes Therapy Afrezza

The U.S. Food and Drug Administration said on Friday it has approved MannKind Corp's inhaled insulin device, Afrezza, capping an arduous journey for the company and its octogenarian founder, Alfred Mann.

Comment?

Related Topix: Food and Drug Administration, Diabetes, Health, Biotech, Insulin (generic), Humulin, Novolin

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••